NTRA: Natera, Inc.
About
Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in Austin, TX.
Current Value
$168.141 Year Return
Current Value
$168.141 Year Return
Key Details
Market Cap
$21.97B
P/E Ratio
-93.84
1Y Stock Return
184.43%
1Y Revenue Growth
54.94%
Dividend Yield
0.00%
Price to Book
23.5
Strategies that include NTRA
Stock's related to NTRA
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| ORGO | 46.52% | $487.88M | +12.54% | 0.00% |
| TSEM | 43.04% | $5.50B | +66.97% | 0.00% |
| VERX | 42.12% | $8.52B | +89.92% | 0.00% |
| ADMA | 40.13% | $4.54B | +413.64% | 0.00% |
| PDFS | 40.12% | $1.17B | -2.33% | 0.00% |
| OKTA | 39.74% | $14.18B | +7.52% | 0.00% |
| KODK | 39.24% | $535.46M | +89.20% | 0.00% |
| PSTG | 38.40% | $19.76B | +78.32% | 0.00% |
| MKSI | 38.19% | $7.46B | +28.80% | 0.78% |
| NVMI | 38.11% | $5.53B | +46.52% | 0.00% |
| ESTA | 37.96% | $1.12B | +89.16% | 0.00% |
| SG | 37.43% | $4.23B | +257.07% | 0.00% |
| MRSN | 37.16% | $306.36M | +22.77% | 0.00% |
| VVV | 37.05% | $5.06B | +12.08% | 0.00% |
| CDNA | 36.49% | $1.29B | +150.99% | 0.00% |
| ALGM | 36.46% | $3.87B | -23.24% | 0.00% |
| FTAI | 36.25% | $15.38B | +239.67% | 0.79% |
| FIX | 36.04% | $16.34B | +131.92% | 0.26% |
| ENTG | 35.93% | $16.03B | -3.68% | 0.37% |
| CLFD | 35.93% | $464.24M | +16.20% | 0.00% |
ETF's related to NTRA
News
Finnhub
SAGITTARIUS is Natera's first interventional trial using SignateraTM to select patients for targeted therapy in early-stage colon cancerApproximately 700-900 patients expected to be enrolled across...
Yahoo
AUSTIN, Texas, December 09, 2024--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, and MyOme, a leading clinical whole genome analysis and polygenic risk modeling company, today announced the launch of an integrated polygenic risk score (iPRS) for personalized breast cancer risk assessment. iPRS, which reports 5-year and lifetime breast cancer risk, offers individuals who receive a negative test result with Natera’s Empower hereditary cancer test the opportunity
Yahoo
Fred Alger Management, an investment management company, released its “Alger Weatherbie Specialized Growth Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here. U.S. equities performed well in the third quarter of 2024, with the S&P 500 rising 5.89%. Utilities and Real Estate sectors outperformed relative to the index while […]
Finnhub
AUSTIN, Texas - Natera, Inc. , a global leader in cell-free DNA and genetic testing, today announced that Obstetrics & Gynecology published the Company's clinical validation study on its cell-free...
Yahoo
We recently compiled a list of the 10 High Growth Healthcare Stocks to Invest in Now. In this article, we are going to take a look at where Natera, Inc. (NASDAQ:NTRA) stands against the other high growth healthcare stocks. Global Healthcare Spending Trends and Investment Opportunities During lean economic times, investing in healthcare stocks is […]
Yahoo
AUSTIN, Texas, December 02, 2024--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that Obstetrics & Gynecology (also known as The Green Journal) published the Company’s clinical validation study on its cell-free DNA (cfDNA) Fetal RhD noninvasive prenatal test (Fetal RhD NIPT).
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.